«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年06期

页码:

888-894

栏目:

论著

出版日期:

2024-12-25

文章信息/Info

Title:

Identification of CA9, an iron death-related gene in lung adenocarcinoma based on the TCGA database

作者:

汪 艳¹; 2; 孙美玲³; 闵凌峰³

225009 扬州,扬州大学医学院¹
211700 淮安,盱眙县人民医院呼吸与危重症医学科²
225001 扬州,扬州大学附属苏北人民医院呼吸与危重症医学科³

Author(s):

Wang Yan¹; 2;  Sun Meiling³;  Min Lingfeng³.

¹Medical college,Yangzhou Universtity, Yangzhou 225009, China; ²Department of Respiratory and Critical Care Medicine, Xuyi People's Hospital,Huaian 211700, China; ³Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou Universtity, Yangzhou 225001, China

关键词:

肺腺癌;  铁死亡;  生物标志物;  相关基因;  预后

Keywords:

Lung Adenocarcinoma;  Ferroptosis;  Biomarkers;  Related gene;  Prognosis

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2024.06.007

摘要:

目的 分析并验证影响肺腺癌(lung adenocarcinoma, LUAD)预后的关键铁死亡(ferroptosis)相关基因及药物敏感性。方法 从癌症基因组图谱数据库(The cancer genome atlas, TCGA)、基因表达数据库(gene expression omnibus, GEO)数据库下载数据。对数据库中下载的转录组表达谱进行差异表达分析、基因本体数据库(gene ontology, GO)和京都的基因和基因组百科全书(Kyoto Encyclopedia of Genes and Genomes, KEGC)富集分析、加权基因共表达网络分析(weighted gene co-expression network analysis, WGCNA)共表达分析,与铁死亡相关基因取交集并进行乘积极限法(Kaplan-Meier, KM)生存分析,获得关键基因,进行药物敏感性分析。结果 TCGA数据集中,LUAD样本和正常样本中共筛选964个差异表达基因(differentially expressed genes, DEGs),其中259个表达上调,705个表达下调。GSE46539数据集中有193个DEGs,其中108个上调,85个下调。964个DEGs进行GO功能富集分析和KEGG通路富集分析显示,DEGs主要参与的生物学功能为细胞外基质组织、细胞外结构组织、外部封装结构组织、细胞黏附的正向调节、伤口愈合、含胶原蛋白的细胞外基质、胶原蛋白三聚体、薄膜筏膜微域、内细胞囊泡、细胞外基质结构成分、糖胺聚糖结合、肝素结合、整合素结合、细胞因子结合。WGCNA共表达分析分别获得5303,362个基因。将TCGA和GSE46539数据集的DEGs、WGCNA与FRGs取交集,确定2个重叠基因配对(couple, CP)和碳酸酐酶9(carbonic anhydrase 9, CA9)。与正常样本相比,CP和CA9高表达于LUAD样本(P<0.001),两者在泛癌中多数为高表达。KM生存分析显示,CA9高表达者生存期短(P<0.05),CP对LUAD生存期的分析差异无统计学意义(P>0.05),CA9是LUAD的危险基因,与2种药物敏感性正相关。结论 生物信息学验证了影响LUAD预后的关键铁死亡相关基因CA9,为LUAD提供了潜在治疗靶点。

Abstract:

Objective To explore and verify the key Ferroptosis related genes and drug sensitivity analysis that affect the prognosis of lung adenocarcinoma(LUAD). Methods Firstly, data were downloaded from TCGA and GEO databases. Secondly, the transcriptome expression profiles downloaded from the databases were subjected to differential expression analysis, GO and KEGG enrichment analysis, WGCNA co-expression analysis, intersection with iron death related genes were taken and KM survival analysis was performed to obtain key genes, and drug sensitivity analysis was performed. Results 964(259 upregulated and were downregulated)and 193 differentially expressed genes(108 upregulated and 85 downregulated)were obtained from TCGA dataset and GEO dataset respectively, which were related to extracellular matrix organization and cell adhesion molecule. 5 303, 362 genes were obtained by WGCNA co-expression analysis, which were intersected with Ferroptosis related genes, and two characteristic genes CP and CA9 were obtained. Compared with normal samples, CP and CA9 were highly expressed in LUAD samples(P<0.001), which were mostly highly expressed in pancarcinoma. KM survival analysis showed that those with high expression of CA9 had a short survival period(P<0.05), while there was no statistically significant difference between CP analysis and LUAD survival period(P>0.05). CA9 was a risk gene of LUAD and positively correlated with the sensitivity of the two drugs. Conclusions The key Ferroptosis related gene CA9 which affects the prognosis of lung adenocarcinoma was explored and verified by bioinformatics, which provides a potential therapeutic target for lung adenocarcinoma.

参考文献/References:

1 Wu F, Wang L, Zhou C. Lung cancer in China: Current and prospect[J]. Curr Opin Oncol, 2021, 33(1): 40-46.
2 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
3 Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10): 1563-1579.
4 农靖颖, 顾艳斐, 张 毅. 晚期非小细胞肺癌免疫治疗预测生物标志物的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 536-538.
5 Wu S, Zhu C, Tang D, et al. The role of ferroptosis in lung cancer[J]. Biomark Res, 2021, 9(1): 82.
6 Yoshida M, Minagawa S, Araya J, et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis[J]. Nat Commun, 2019, 10(1): 3145.
7 Robinson MD, Mccarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data[J]. Bioinformatics, 2010, 26(1): 139-140.
8 Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
9 Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC bioinformatics, 2008, 9(1): 559.
10 Li J, Cao F, Yin H, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
11 Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice[J]. Science, 2020, 368(6486): 85-89.
12 Dai E, Han L, Liu J, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway[J]. Nat Commun, 2020, 11(1): 6339.
13 Becker HM. Carbonic anhydrase IX and acid transport in cancer[J]. Br J Cancer, 2020, 122(2): 157-167.
14 Mcdonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics[J]. Oncotarget, 2012, 3(1): 84-97.
15 Li Z, Jiang L, Chew SH, et al. Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia[J]. Redox Biol, 2019, 26: 101297.
16 Song X, Zhu S, Xie Y, et al. JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice[J]. Gastroenterology, 2018, 154(5): 1480-1493.
17 Wen J, Yang T, Mallouk N, et al. Urinary exosomal CA9 mRNA as a novel liquid biopsy for molecular diagnosis of bladder cancer[J]. Int J Nanomedicine, 2021, 16: 4805-4811.
18 Gu M. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma[J]. Int J Clin Exp Pathol, 2015, 8(1): 862-866.
19 Guan C, Ouyang D, Qiao Y, et al. CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients[J]. J Cell Mol Med, 2020, 24(10): 5832-5841.
20 Wang S, Fu Z, Wang Y, et al. Correlation of carbonic anhydrase 9(CA9)with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma[J]. Ann Transl Med, 2020, 8(22): 1521.
21 Sowa T, Menju T, Chen-Yoshikawa TF, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression[J]. Cancer Med, 2017, 6(1): 288-297.
22 Giatromanolaki A, Harris AL, Banham AH, et al. Carbonic anhydrase 9(CA9)expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration[J]. Br J Cancer, 2020, 122(8): 1205-1210.
23 Zhang C, Lu X, Liu X, et al. Carbonic anhydrase IX controls vulnerability to ferroptosis in gefitinib-resistant lung cancer[J]. Oxid Med Cell Longev, 2023, 2023: 1367938.
24 Stewart DJ, Nunez MI, Behrens C, et al. Membrane carbonic anhydrase IX expression and relapse risk in resected stage Ⅰ-Ⅱ non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(5): 675-684.
25 Janmaat ML, Rodriguez JA, Jimeno J, et al. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling[J]. Mol Pharmacol, 2005, 68(2): 502-510.
26 Wyer S, Townsend DM, Ye Z, et al. Recent advances and limitations in the application of kahalalides for the control of cancer[J]. Biomed Pharmacother, 2022, 148: 112676.
27 Arkenau H, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies[J]. 2012, 23(5): 1307-1313.
28 Dent SF, Gelmon KA, Chi KN, et al. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies[J]. Invest New Drugs, 2013, 31(6): 1522-1529.
29 Lucas M, Lynley VM, Andrew DJP, et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases)in children and adolescents with solid tumors: A Cancer Research UK study[J]. Clin Cancer Res, 2015, 21(2): 267-273.
30 Moreno L, Marshall LV, Pearson AD, et al. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis[J]. Clin Cancer Res, 2015, 21(2): 267-273.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金资助项目(81870033)
通信作者: 闵凌峰, Email: minlingfeng@126.com

常用功能

更新日期/Last Update: 2024-12-25